[PDF] Top 20 CAR therapy: the CD19 paradigm
Has 10000 "CAR therapy: the CD19 paradigm" found on our website. Below are the top 20 most common "CAR therapy: the CD19 paradigm".
CAR therapy: the CD19 paradigm
... of CAR T cell activity that exhibits variable magnitude. CD19 CAR T cells often induce fever accompanied by cytokine release, but a substantial cytokine response may induce hemodynamic and cardiac ... See full document
10
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
... that CD19 is a viable target for elimin- ation of various hematologic malignancies, but improve- ments concerning T cell phenotypic abundance, use of alternative costimulatory domains, and combining anti- ... See full document
12
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
... the paradigm of clinical cancer ...T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercially approved by the US Food and Drug Administration for ... See full document
11
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
... lack CD19 expression [9], the CNS complications might less probably result from direct interactions be- tween CD19+ cells and ...penetrating CAR T ...residual CD19+ leukemia cells less than ... See full document
5
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization
... regulatable CAR architectures and safety switches has been partially driven by the severe adverse events (SAEs) occasionally seen in CD19 CAR T cell clinical ...from CD19 CAR T cell ... See full document
19
<p>Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma</p>
... combining CAR-T cell therapy with DAC therapy, we tested whether pretreated lymphoma cells with DAC would in fl uence their suscept- ibility to CAR-T cell-mediated ...with CAR-T cells ... See full document
12
<p>Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy</p>
... The patient was given imatinib (400 mg/d) starting from January 13, 2017, but resistance occurred quickly after half a year. Gene sequencing showed Y253H mutation in the ABL1 kinase domain (Figure 1). As a result, ... See full document
7
Targeted antibody mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
... fer, which is important in situations where toxicity might neces- sarily be tolerated to allow tumor eradication to be complete, but still be reversible at late times after T cell transfer. Our studies showed that the ... See full document
12
Rejection of Experimental Hodgkins Lymphoma by T Cells Engineered with a CD19 Chimeric Antigen Receptor
... 7 CD19-CAR engineered cells or CTL-A cells (an EBV-specific CTL, matching two MHC loci with ...no therapy developed sc tumors as a result of sc injection of 5 × 10 6 L591 ...received ... See full document
9
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
... systemic therapy for acute GVHD ...donor-derived CAR-T cells [9], and conditions were difficult to distinguish, making the steroid use more ...of CAR-T cells, whereby the short-term and long-term ... See full document
9
Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report
... established therapy and best option for many malignant ALL cases, however, disease relapse remains the main reason of ...T-cell therapy has become a promising treatment for patients with advanced blood ... See full document
6
CD19 CAR T cell product and disease attributes predict leukemia remission durability
... with CD19 antigen–induced activation following adoptive ...of CAR T cells that mediate subsequent postremis- sion immunosurveillance for minimal residual leukemic burden that takes months to ... See full document
11
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor
... of CAR expression and address the potential for off-frame transcription, codons were optimized and all internal open reading frames (ORFs) were removed with one exception, creating the C4opt-27z ...A ... See full document
18
<p>Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature</p>
... of CAR T cells ther- apy synergistic responses as compared to targeting a single antigen, improving the response ...expressed CD19 and CD22, the patient received donor-derived anti-CD22 and anti-CD19 ... See full document
7
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
... in these patients with CLL and NHL, with CRS grade I/ II, 64%; grade III, 7%; grade IV, none; and acute neuro- toxicity, 34%. Cytopenias requiring G-CSF and/ or trans- fusion support were among the notable long-term ... See full document
11
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... (CAR-T) therapy for B-cell lymphocyte malignancies targeting CD19 places it in a rapidly growing field in cancer immunotherapy for both hematological and solid ...developed CAR-T immunotherapy ... See full document
12
Phase I trials using Sleeping Beauty to generate CD19 specific CAR T cells
... generate CD19-spe- cific CAR T cells for human ...of CD19-specific CAR T cells after con- ventional autologous and allogeneic HSCT in efforts to improve the GVT effects and thus decrease the ... See full document
15
Clinical trials of CAR-T cells in China
... analyzed CAR-T trials in China. Most CAR-T trials are employing autologous T ...cells. CD19 is the most commonly targeted ...in CAR-T trials. Solid tumors remain a significant challenge for ... See full document
10
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
... 19-28z CAR study, 32 of the 53 patients (67%) had MRD-negative CR whereas 9 patients entered CR with still positive MRD (bone marrow blasts > = ...post CAR-T ...with CD19− ...after CAR-T ... See full document
5
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
... (CAR-T) therapy, as one of the most promising targeted immunotherapies, has drawn extensive attention and resulted in multiple ...ies, CD19-directed CAR-T cells (CD19 CAR-T) can ... See full document
7
Related subjects